

Dear Shareholder 親愛的股東：

The board of directors (the "Board") of JHL Biotech, Inc. (TPEX: 6540) ("JHL" or the "Company") on December 8, 2017 resolved to initiate the process to voluntarily terminate trading of JHL shares ("Shares") on Emerging Stock Market of Taipei Exchange (TPEX) and withdrawal of public issuance of the Shares (the "Voluntary Delisting") by submitting relevant applications to the regulators pursuant to applicable procedures after the proposal is approved by the shareholders meeting.

本公司（喜康(開曼)控股股份有限公司，興櫃股票代號：6540）董事會於106年12月8日決議自願終止興櫃股票櫃檯買賣暨撤銷公開發行（“自願撤興櫃”）並將於股東會同意後依法定程序向主管機關提出申請。

The Board believes the Voluntary Delisting is in the best interests of the Company and its shareholders. It better positions JHL to pursue its planned expansion activities and actively explore various, broad fundraising strategies (including a potential listing on an overseas exchange).

本公司董事會相信自願撤興櫃將為本公司及全體股東帶來最佳利益。有助於喜康計畫中的業務擴張，並使公司得以積極探索更廣泛多元的資金募集策略（包括可能在海外資本市場掛牌交易）。

The Company tentatively plans to convene a shareholder meeting on or about February 1, 2018 to seek shareholders' approval for the Voluntary Delisting. If approved, shareholders may (1) do nothing and continue remain as a shareholder, (2) continue to sell shares on the market up to the delisting date, or (3) request for share repurchase by the Company, in accordance with applicable rules. In the event JHL is listed in an overseas exchange in the future, the Company will assist all then remaining shareholders to open a brokerage account in the relevant jurisdiction.

本公司暫定將於2018年2月1日召開臨時股東會表決自願撤興櫃及相關的議程。一旦股東會通過自願撤興櫃的決議，公司股東得(1)不須進行任何操作並繼續持有本公司股份；(2)在櫃檯買賣中心宣告喜康股票停止興櫃交易前在公開市場出售其股份；或(3)依櫃檯買賣中心法定程序要求公司買回其股份。未來若喜康在境外其他證券交易所上市，公司將協助股東在該上市地的券商處開立證券帳戶。

The Company truly believes access to worldwide capital markets will help the Company accomplish more sooner, and for the benefit of our shareholders. We sincerely hope that you will not only vote to support the Voluntary Delisting, but also remain with us for the exciting steps and success ahead. So, we attach the undertaking for your execution to support the Board proposal as well as to remain as a shareholder of the Company. Thank you.

我們衷心相信全球資本市場將協助本公司更快、更好的實現我們的願景並幫股東創造更大的價值。我們誠心希望我們的股東不只投票支持自願撤興櫃，並且跟我們一起走向令人興奮及成功的未來。在此懇請股東簽署所附的承諾書，支持董事會議案及繼續持有本公司股票。

Please send the signed original undertaking to the following contact information, by Friday, January 26, 2018, and promptly send an advance scan/image to the below: 請將簽署完成之承諾書正本於 2018年1月26日星期五之前寄至以下地址，以及立即掃描或拍照此承諾書並寄至以下電子信箱：

JHL BIOTECH, INC. (喜康(開曼)控股股份有限公司)

302 新竹縣竹北市生醫路2段18號3樓

3F., No.18, Sec. 2, Shengyi Rd., Zhubei City,

Hsinchu County 302, Taiwan (R.O.C.)

Contact 聯絡人: Jill Liu (劉淑娟), +886 3 658 3899 ext 201, jliu@jhlbiotech.com

Amber Chen (陳夢婷), +886 3 658 3899 ext 202, achen@jhlbiotech.com

If you need more copies of the undertaking, please download from JHL website: www.jhlbiotech.com under Shareholder Services Section.

若您需要更多承諾書，請上喜康官網(www.jhlbiotech.com)股東服務專區下載。

(This document is not intended to, and shall not, constitute an offer to sell or a solicitation of an offer to buy any Shares. The statement regarding JHL's future plans and its ability to complete the proposed Voluntary Delisting and maximize shareholder value, represent only the current expectations, assumptions, estimates and projections of the Company. 本文件並非意在且不應構成任何購買或出售喜康股份的要約或要約之引誘。有關喜康未來之發展規劃及其完成自願撤興櫃與實現股東價值最大化能力的描述，僅反應公司目前的預期、假設、估計和判斷。)